

The global epidemiology of herpes zoster

Neurology

81, 928-930

DOI: [10.1212/wnl.0b013e3182a3516e](https://doi.org/10.1212/wnl.0b013e3182a3516e)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Population-Based Study of the Epidemiology of Herpes Zoster in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 1706.	1.1	53
2	Introduction of a national herpes zoster (shingles) immunization programme and impact on neuropathic pain. <i>European Journal of Pain</i> , 2014, 18, 1217-1218.	1.4	2
4	Neurological complications of varicella zoster virus reactivation. <i>Current Opinion in Neurology</i> , 2014, 27, 356-360.	1.8	132
6	Paediatric neurology: a year of DNA technology. <i>Lancet Neurology</i> , The, 2014, 13, 16-18.	4.9	5
8	The Neuralgias: Diagnosis and Management. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 459.	2.0	29
9	Randomized placebo-controlled clinical trial showed cold atmospheric argon plasma relieved acute pain and accelerated healing in herpes zoster. <i>Clinical Plasma Medicine</i> , 2014, 2, 50-55.	3.2	52
11	Infecciones cut�neas. <i>Medicine</i> , 2014, 11, 2755-2763.	0.0	0
12	Mandibular Osteonecrosis and Ramsay Hunt Syndrome Following a Case of Herpes Zoster. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014, 72, 1974.e1-1974.e6.	0.5	2
13	Incidence and predictors of herpes zoster among antiretroviral therapy-na�ve patients initiating HIV treatment in Johannesburg, South Africa. <i>International Journal of Infectious Diseases</i> , 2014, 23, 56-62.	1.5	20
14	Neuropathic cancer pain: What we are dealing with? How to manage it?. <i>OncoTargets and Therapy</i> , 2014, 7, 599.	1.0	35
15	Varicella-Zoster Virus Vasculopathy: The Growing Association Between Herpes Zoster and Strokes. <i>American Journal of the Medical Sciences</i> , 2015, 350, 243-245.	0.4	10
16	Incidence of herpes zoster and associated events including stroke�a population-based cohort study. <i>BMC Infectious Diseases</i> , 2015, 15, 488.	1.3	53
17	Incidence and risk factors for herpes zoster in patients undergoing liver transplantation. <i>Transplant Infectious Disease</i> , 2015, 17, 671-678.	0.7	26
18	Herpes zoster vaccination in the elderly subjects: improving awareness and uptake. <i>Patient Intelligence</i> , 2015, , 15.	0.2	0
19	Neurological Sequale of Varicella Zoster Virus Infection. <i>Journal of Neuroinfectious Diseases</i> , 2015, 01, .	0.2	0
20	Increasing Trends of Herpes Zoster in Australia. <i>PLoS ONE</i> , 2015, 10, e0125025.	1.1	40
21	Herpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention and Treatment. <i>Korean Journal of Pain</i> , 2015, 28, 177-184.	0.8	107
22	Evasion of Early Antiviral Responses by Herpes Simplex Viruses. <i>Mediators of Inflammation</i> , 2015, 2015, 1-16.	1.4	55

#	ARTICLE	IF	CITATIONS
23	88-Year-Old Man With Mental Status Changes and Vesicular Lesions. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1131-1134.	1.4	0
24	Management and Prevention of Herpes Zoster Ocular Disease. <i>Cornea</i> , 2015, 34, S3-S8.	0.9	24
25	Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 319-342.	1.4	12
26	Reducing the burden of Herpes Zoster in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 101-107.	1.4	13
27	Altered Phenotype and Functionality of Varicella Zoster Virus-Specific Cellular Immunity in Individuals With Active Infection. <i>Journal of Infectious Diseases</i> , 2015, 211, 600-612.	1.9	62
28	How sex and age affect immune responses, susceptibility to infections, and response to vaccination. <i>Aging Cell</i> , 2015, 14, 309-321.	3.0	552
29	Evaluation of the economic burden of Herpes Zoster (HZ) infection. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 245-262.	1.4	40
30	Herpes zoster ophthalmicus following onabotulinumtoxinA administration for chronic migraine: A case report and literature review. <i>Cephalalgia</i> , 2015, 35, 443-448.	1.8	12
33	Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. <i>Therapeutic Advances in Vaccines</i> , 2015, 3, 109-120.	2.7	155
34	Immune Evasion by Herpes Simplex Viruses. , 0, , .		7
35	Cerebrospinal Fluid Cytokines and Neurotrophic Factors in Human Chronic Pain Populations: A Comprehensive Review. <i>Pain Practice</i> , 2016, 16, 183-203.	0.9	47
36	Mitochondrial Haplogroups as a Risk Factor for Herpes Zoster. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw184.	0.4	6
37	Varicella zoster virus-associated morbidity and mortality in Africa: a systematic review protocol. <i>BMJ Open</i> , 2016, 6, e010213.	0.8	9
38	Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster. <i>Drug Safety</i> , 2016, 39, 823-840.	1.4	28
39	Neuropatía motora posterior a herpes zoster. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2016, 23, 372-374.	0.0	0
40	Early application of low-level laser may reduce the incidence of postherpetic neuralgia (PHN). <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 572-577.	0.6	17
41	Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw205.	0.4	81
43	Risk of Stroke and Myocardial Infarction After Herpes Zoster in Older Adults in a US Community Population. <i>Mayo Clinic Proceedings</i> , 2016, 91, 33-44.	1.4	57

#	ARTICLE	IF	CITATIONS
44	Janus kinase inhibitors for rheumatoid arthritis. <i>Current Opinion in Chemical Biology</i> , 2016, 32, 29-33.	2.8	112
45	Persistent dilemmas in zoster eye disease. <i>British Journal of Ophthalmology</i> , 2016, 100, 56-61.	2.1	19
46	A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia. <i>Internal Medicine Journal</i> , 2017, 47, 491-500.	0.5	15
47	Herpes Zoster Overlying Recently Placed Central Venous Access Site: A Case Report. <i>Canadian Journal of Emergency Medicine</i> , 2017, 19, 75-78.	0.5	1
48	Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007-2014). <i>Journal of NeuroVirology</i> , 2017, 23, 451-459.	1.0	23
49	Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. <i>Trials</i> , 2017, 18, 24.	0.7	16
50	Prognostic value of Hutchinson's sign for ocular involvement in herpes zoster ophthalmicus. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 563-564.	0.4	2
51	The Epidemiology and Natural History of Herpes Zoster and Postherpetic Neuralgia. , 2017, , 25-44.		3
52	The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study. <i>Journal of Dermatological Science</i> , 2017, 88, 36-45.	1.0	61
53	Acupuncture plus moxibustion for herpes zoster: A systematic review and meta-analysis of randomized controlled trials. <i>Dermatologic Therapy</i> , 2017, 30, e12468.	0.8	19
54	Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice-based cohort study. <i>Journal of Dermatology</i> , 2017, 44, 414-422.	0.6	31
55	Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 574-578.	1.4	18
56	Herpes Zoster in the Older Adult. <i>Infectious Disease Clinics of North America</i> , 2017, 31, 811-826.	1.9	96
58	Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 668-672.	1.9	24
59	A method for detecting rash and fever illness-associated viruses using multiplex reverse transcription polymerase chain reaction. <i>Microbiology and Immunology</i> , 2017, 61, 337-344.	0.7	3
60	Die prognostische Bedeutung des Hutchinson'schen Zeichens für eine okuläre Beteiligung bei Herpes zoster ophthalmicus. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 563-564.	0.4	2
61	A case control study on family history as a risk factor for herpes zoster and associated outcomes, Beijing, China. <i>BMC Infectious Diseases</i> , 2017, 17, 334.	1.3	9
62	European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 9-19.	1.3	62

#	ARTICLE	IF	CITATIONS
63	Adult asthma is associated with an increased risk of herpes zoster: A population-based cohort study. <i>Journal of Asthma</i> , 2017, 54, 250-257.	0.9	22
64	Pain, Itch, Quality of Life, and Costs after Herpes Zoster. <i>Pain Practice</i> , 2017, 17, 738-746.	0.9	20
65	The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥50 Years in Japan: Results of a Markov Model Analysis. <i>Dermatology and Therapy</i> , 2018, 8, 269-284.	1.4	13
66	Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study. <i>Journal of Infection</i> , 2018, 76, 475-482.	1.7	32
67	Effects of gabapentin, pregabalin and gastroretentive gabapentin on simulated driving, daytime sedation and cognition. <i>Pain Management</i> , 2018, 8, 297-306.	0.7	5
69	The risk of herpes zoster in patients with ankylosing spondylitis: Analysis of the Korean National Health Insurance Service "Sample cohort database. <i>Modern Rheumatology</i> , 2018, 28, 168-173.	0.9	17
70	Review for Disease of the Year: Varicella Zoster Virus-Induced Anterior Uveitis. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 171-177.	1.0	14
71	Management of vaccination in rheumatic disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 720-734.	1.4	8
72	Clinical and Epidemiological Profile of Herpes Zoster; A Cross-Sectional Study from Tertiary Hospital. <i>Med Phoenix</i> , 2018, 3, 60-65.	0.0	0
73	VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs. <i>Arthritis Research and Therapy</i> , 2018, 20, 252.	1.6	8
74	Quantifying the incidence and burden of herpes zoster in New Zealand general practice: a retrospective cohort study using a natural language processing software inference algorithm. <i>BMJ Open</i> , 2018, 8, e021241.	0.8	8
76	<i>Viral Diseases.</i> , 2018, , 269-296.		0
77	Policy Statement. <i>Ophthalmology</i> , 2018, 125, 1813-1816.	2.5	5
78	<i>Zoster Vaccines.</i> , 2018, , 1268-1281.e6.		3
79	<i>Etiology of Head Pain.</i> , 2018, , 13-19.		0
80	Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. <i>International Journal of Molecular Sciences</i> , 2018, 19, 379.	1.8	252
81	Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. <i>Expert Review of Vaccines</i> , 2018, 17, 619-634.	2.0	77
82	A retrospective case series of segmental zoster paresis of limbs: clinical, electrophysiological and imaging characteristics. <i>BMC Neurology</i> , 2018, 18, 121.	0.8	27

#	ARTICLE	IF	CITATIONS
84	The Neuralgias. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 69.	2.0	13
85	Validated HPLC Method for the simultaneous determination of acyclovir and co-administered vitamin B ₃ and gabapentin in spiked human plasma. <i>Separation Science Plus</i> , 2018, 1, 475-482.	0.3	3
86	Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 723-732.	1.0	14
87	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 988-1000.	4.6	136
88	Analysis of the Risk Factors for Postherpetic Neuralgia. <i>Dermatology</i> , 2019, 235, 426-433.	0.9	16
89	The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial. <i>Vaccine</i> , 2019, 37, 5877-5885.	1.7	13
91	Association between Herpes Zoster and Osteoporosis: A Nested Case-Control Study Using a National Sample Cohort. <i>BioMed Research International</i> , 2019, 2019, 1-7.	0.9	5
92	Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. <i>Vaccine</i> , 2019, 37, 6262-6267.	1.7	18
93	Neurological and Ophthalmological Manifestations of Varicella Zoster Virus. <i>Journal of Neuro-Ophthalmology</i> , 2019, 39, 220-231.	0.4	35
95	Herpes Simplex Virus Evasion of Early Host Antiviral Responses. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 127.	1.8	89
96	Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2865-2872.	1.4	22
97	Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial. <i>PLoS ONE</i> , 2019, 14, e0217335.	1.1	18
98	Tools and Methods for Real-World Evidence Generation. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 275-289.	0.8	9
99	Humoral immunity to varicella zoster virus is altered in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 2493-2500.	1.0	8
100	Herpes Zoster Vaccination: A Vaccine to Prevent Pain. <i>Practical Issues in Geriatrics</i> , 2019, , 91-95.	0.3	0
101	Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1094-1106.	0.9	12
102	The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz007.	0.4	14
103	Incidence and risk factors for herpes zoster after adult liver transplantation. <i>Annals of Surgical Treatment and Research</i> , 2019, 96, 95.	0.4	13

#	ARTICLE	IF	CITATIONS
104	Epidemiology and clinical characteristics of herpes zoster in a tertiary care hospital in Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2019, 23, 143-145.	0.3	7
105	Should Antiviral/Anti-Varicella Zoster Virus Treatment Be Used in Patients With Giant Cell Arteritis?. <i>Journal of Neuro-Ophthalmology</i> , 2019, 39, 134-141.	0.4	3
106	Increased risk of lymphoid malignancy in patients with herpes zoster: a longitudinal follow-up study using a national cohort. <i>BMC Cancer</i> , 2019, 19, 1148.	1.1	3
107	Efficacy and Safety of Computed Tomography-Guided Pulsed Radiofrequency Modulation of Thoracic Dorsal Root Ganglion on Herpes Zoster Neuralgia. <i>Neuromodulation</i> , 2019, 22, 108-114.	0.4	24
108	Herpes zoster infection and statins: which implications in clinical practice?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 93-99.	1.3	4
109	Herpes zoster does not increase the risk of sudden sensory neural hearing loss: a longitudinal follow-up study using a national sample cohort. <i>International Journal of Audiology</i> , 2020, 59, 173-178.	0.9	0
110	The risk of herpes zoster among patients with ankylosing spondylitis: A population-based cohort study in Taiwan. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 181-188.	0.9	9
111	Identification of herpes zoster high-risk group using Charlson comorbidity index: A nationwide retrospective cohort study. <i>Journal of Dermatology</i> , 2020, 47, 47-53.	0.6	5
112	Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. <i>Vaccine</i> , 2020, 38, 3489-3500.	1.7	20
113	A Rare Case of an Immunocompetent Male With Zoster Meningitis. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2020, 8, 232470962095221.	0.3	1
114	Varicella vaccination in Italy and Germany – different routes to success: a systematic review. <i>Expert Review of Vaccines</i> , 2020, 19, 843-869.	2.0	14
115	P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S460-S461.	0.6	0
116	Segmental zoster paresis of unilateral upper extremity. <i>Medicine (United States)</i> , 2020, 99, e20466.	0.4	11
117	Botulinum Neurotoxin for the Treatment of Neuropathic Pain. <i>Frontiers in Neurology</i> , 2020, 11, 716.	1.1	35
118	LncRNA KCNA2-AS regulates spinal astrocyte activation through STAT3 to affect postherpetic neuralgia. <i>Molecular Medicine</i> , 2020, 26, 113.	1.9	10
119	Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates. <i>Vaccine</i> , 2020, 38, 5793-5802.	1.7	40
120	Intravenous Administration of Vitamin C in the Treatment of Herpes Zoster-Associated Pain: Two Case Reports and Literature Review. <i>Pain Research and Management</i> , 2020, 2020, 1-8.	0.7	3
121	CT-Guided Pulsed Radiofrequency at Different Voltages in the Treatment of Postherpetic Neuralgia. <i>Frontiers in Neuroscience</i> , 2020, 14, 579486.	1.4	17

#	ARTICLE	IF	CITATIONS
122	Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination. <i>Journal of Infectious Diseases</i> , 2021, 224, 2025-2034.	1.9	21
123	Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. <i>Frontiers in Immunology</i> , 2020, 11, 717.	2.2	63
124	Efficacy comparison of different acupuncture methods for herpes zoster. <i>Medicine (United States)</i> , 2020, 99, e20833.	0.4	1
125	P537 Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S458-S460.	0.6	0
126	P538 Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis treated with ustekinumab. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S460-S460.	0.6	7
127	Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2628-2633.	1.4	13
128	Novel Technologies to Improve Vaccines for Older Adults. <i>Interdisciplinary Topics in Gerontology and Geriatrics</i> , 2020, 43, 218-233.	2.6	2
129	High Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis. <i>Clinical Infectious Diseases</i> , 2021, 72, 1350-1357.	2.9	11
130	A systematic literature review to assess the burden of herpes zoster disease in China. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 165-179.	2.0	19
131	Risk factors for herpes zoster in patients with rheumatic diseases: a nationwide cohort study in Korea. <i>Rheumatology</i> , 2021, 60, 2427-2433.	0.9	8
132	Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIb, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients. <i>Vaccine</i> , 2021, 39, 6-10.	1.7	9
133	Infections of the Cornea and Conjunctiva. , 2021, , .		2
134	Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. <i>Rheumatology</i> , 2021, 60, 1226-1233.	0.9	26
136	The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2050-2057.	1.4	5
137	Incidence and disease burden of herpes zoster in the population aged ≥50 years in China: Data from an integrated health care network. <i>Journal of Infection</i> , 2021, 82, 253-260.	1.7	38
138	Severe brachial plexopathy secondary to shingles (herpes zoster). <i>Age and Ageing</i> , 2021, 50, 1001-1003.	0.7	1
139	Pathobiology and treatment of viral keratitis. <i>Experimental Eye Research</i> , 2021, 205, 108483.	1.2	23
140	Efficacy of Acupuncture for Herpes Zoster: A Systematic Review and Meta-Analysis. <i>Complementary Medicine Research</i> , 2021, 28, 463-472.	0.5	7

#	ARTICLE	IF	CITATIONS
141	Pulsed Radiofrequency of the Trigeminal Ganglion for Treating Postherpetic Neuralgia of the Ophthalmic Branch. <i>Pain Research and Management</i> , 2021, 2021, 1-6.	0.7	6
143	Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4132-4143.	1.4	6
144	Vaccination in Patients with Chronic Lymphocytic Leukemia: Current Problems. <i>Epidemiologiya i Vaktsinoprofilaktika</i> , 2021, 20, 91-106.	0.2	1
145	Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3735-3746.	1.4	10
146	The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. <i>Clinical Infectious Diseases</i> , 2022, 74, 1459-1467.	2.9	41
147	Association between Neutrophil-Lymphocyte Ratio and Herpes Zoster Infection in 1688 Living Donor Liver Transplantation Recipients at a Large Single Center. <i>Biomedicines</i> , 2021, 9, 963.	1.4	2
148	A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations. <i>Expert Review of Vaccines</i> , 2021, 20, 1065-1075.	2.0	18
149	Chronic and Recurrent Herpes Zoster Ophthalmicus. <i>Medicina (Lithuania)</i> , 2021, 57, 999.	0.8	6
150	Herpes zoster in outpatient departments of healthcare centers in India: a review of literature. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4155-4162.	1.4	7
151	Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis. <i>Korean Journal of Pain</i> , 2021, 34, 509-533.	0.8	15
152	Reemerging Viral Infections: Implications of Lack of Vaccination. <i>Updates in Clinical Dermatology</i> , 2021, , 111-129.	0.1	0
153	Robust Skin Disease Classification by Distilling Deep Neural Network Ensemble for the Mobile Diagnosis of Herpes Zoster. <i>IEEE Access</i> , 2021, 9, 20156-20169.	2.6	24
154	Central nervous system infections produced by varicella zoster virus. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 273-278.	1.3	50
155	Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine. <i>Journal of Medical Microbiology</i> , 2016, 65, 1363-1369.	0.7	16
156	Trigeminal herpes zoster: early recognition and treatment are crucial. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014208673-bcr2014208673.	0.2	13
157	Manipulation of the Innate Immune Response by Varicella Zoster Virus. <i>Frontiers in Immunology</i> , 2020, 11, 1.	2.2	516
158	Epidemiology of herpes zoster in the State of Qatar, 2012-2017. <i>Qatar Medical Journal</i> , 2020, 2020, 1.	0.2	6
159	Bilateral Pupillary Involvement as a Clinical Presentation of Herpes Zoster Ophthalmicus. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 87-91.	1.0	1

#	ARTICLE	IF	CITATIONS
160	FOTOBİOMODULASYONUN NO TRATAMENTO DE NEURALGIA PÓS-HERPÉTICA: CASO CLÍNICO. Revista UniVap, 2021, 27, .	0.1	0
161	No Consistent Evidence of Decreased Exposure to Varicella-Zoster Virus Among Older Adults in Countries with Universal Varicella Vaccination. Journal of Infectious Diseases, 2022, 225, 413-421.	1.9	6
162	An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine. Drug Safety, 2021, 44, 1341-1353.	1.4	5
163	Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immunity and Ageing, 2021, 18, 38.	1.8	20
164	Herpes Viral Retinochoroiditis. , 2016, , 1-14.		0
165	Boceprevir-induced Herpes Zoster. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 161-162.	0.1	0
166	Spontaneous pneumothorax as an uncommon complication of herpes zoster infection. Journal of Surgery and Medicine, 0, , .	0.0	0
167	Current perspective on treating herpes zoster and postherpetic neuralgia. Dermatologie Pro Praxi, 2018, 12, 182-185.	0.1	0
168	Population-Based Epidemiologic Study on Herpes Zoster in Korea: Seven-Year Nationwide Analysis from 2010 to 2016. Annals of Dermatology, 2019, 31, 486.	0.3	5
169	Pain management and stroke prevention in HHV-3-associated infection. Journal of Clinical Practice, 2019, 10, 74-84.	0.2	0
170	Herpes Viral Retinochoroiditis. , 2020, , 347-357.		0
171	Herpes Zoster and the Zoster Eye Disease Study (ZEDS). , 2020, , 63-71.		0
172	Herpes Zoster Tanımlanmış ve Takip Edilen Hastaların Demografik, Klinik ve Laboratuvar Özelliklerinin Değerlendirilmesi. Ankara Eczacılık Ve Araştırma Hastanesi Tıp Dergisi, 2020, 53, 33-40.	0.1	3
173	External therapy of Chinese medicine for postherpetic neuralgia. Medicine (United States), 2020, 99, e23270.	0.4	1
174	Viral Dermatoses in HIV/AIDS Patients. , 2020, , 37-79.		0
176	Extracranial Herpetic Paresis. , 0, , .		0
178	Zoster duplex: a clinical report and etiologic analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 11020-5.	1.3	5
180	Vaccines and Vaccination Strategies for Older Adults. Healthy Ageing and Longevity, 2022, , 119-164.	0.2	1

#	ARTICLE	IF	CITATIONS
181	Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence. <i>Journal of Medical Economics</i> , 2022, 25, 26-37.	1.0	5
182	Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids. <i>Modern Rheumatology</i> , 2021, .	0.9	4
184	Patient-reported quality of life in patients suffering from acute herpes zoster—a systematic review with meta-analysis. <i>British Journal of Pain</i> , 2022, 16, 404-419.	0.7	3
186	Neurotrophic Keratopathy After Herpes Zoster Ophthalmicus. <i>Cornea</i> , 2022, 41, 1433-1436.	0.9	6
187	A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine. <i>American Journal of Epidemiology</i> , 2022, 191, 957-964.	1.6	7
189	Sudden Onset of Unilateral Facial Paralysis with Ear Pruritus: A Quiz. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00675.	0.6	0
191	A Clinico-Epidemiological Study of Cases of Herpes Zoster in a Tertiary Care Hospital. <i>Journal of Skin and Stem Cell</i> , 2022, 9, .	0.1	1
192	An acyclic phosphonate prodrug of HPMPC is effective against VZV in skin organ culture and mice. <i>Antiviral Research</i> , 2022, 199, 105275.	1.9	4
193	The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial. <i>Journal of Infection</i> , 2022, 84, 490-498.	1.7	7
194	The Number Needed to Vaccinate (NNV) against herpes zoster: a systematic review with meta-analysis. <i>Infectious Diseases</i> , 2022, 54, 356-366.	1.4	1
195	Meningitis/meningoencephalitis caused by varicella zoster virus reactivation: a retrospective single-center case series study.. <i>American Journal of Translational Research (discontinued)</i> , 2022, 14, 491-500.	0.0	0
196	Characteristics of herpes zoster infection in patients with COVID-19: a systematic scoping review. <i>International Journal of Dermatology</i> , 2022, 61, 1087-1092.	0.5	4
197	Oleanolic Acid Derivative AXX-18 Exerts Antiviral Activity by Inhibiting the Expression of HSV-1 Viral Genes UL8 and UL52. <i>Viruses</i> , 2022, 14, 1287.	1.5	1
198	A Rare Complication of Herpes Zoster: Segmental Zoster Paresis. <i>Cureus</i> , 2022, , .	0.2	3
199	Fire Needling Acupuncture for Adult Patients with Acute Herpes Zoster: Protocol of a Systematic Review and Meta-Analysis. <i>Journal of Pain Research</i> , 0, Volume 15, 2161-2170.	0.8	0
200	An unusual complication of varicella zoster. <i>Journal of the Royal College of Physicians of Edinburgh</i> , The, 0, , 147827152211246.	0.2	1
201	Skin neuropathy and immunomodulation in diseases. <i>Fundamental Research</i> , 2024, 4, 218-225.	1.6	1
202	Identifying optimal vaccination scenarios to reduce varicella zoster virus transmission and reactivation. <i>BMC Medicine</i> , 2022, 20, .	2.3	0

#	ARTICLE	IF	CITATIONS
203	The health and economic impact of switching vaccines in universal varicella vaccination programs using a dynamic transmission model: An Israel case study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	0
204	Epidemiology of Herpes Zoster in Adults in Mexico: A Retrospective Database Analysis. <i>Infectious Diseases and Therapy</i> , 2023, 12, 131-141.	1.8	1
205	Herpes Zoster in Hospitalized Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 0, Publish Ahead of Print, .	1.1	0
206	Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 27-41.	0.9	13
207	Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines. <i>Viruses</i> , 2022, 14, 2667.	1.5	7
208	Willingness to accept herpes zoster vaccines and the influencing factors in China. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	4
209	Economic burden of herpes zoster in Latin America: A systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
210	An Atypical Rash in Disseminated Herpes Zoster: A Case Report. <i>Cureus</i> , 2023, , .	0.2	1
211	Lifetime risk of herpes zoster in the population of Beijing, China. <i>Public Health in Practice</i> , 2023, 5, 100356.	0.7	0
212	The Clinical Thinking of Acupuncture Treatment in Postherpetic Neuralgia Based on the Theory of "All Pain, Itchiness or Sore Disorders Connecting to the Heart". <i>Traditional Chinese Medicine</i> , 2023, 12, 119-123.	0.1	0
213	Neurophysiological confirmation of phrenic nerve affection in patient with dyspnea and herpes zoster. <i>Vojnosanitetski Pregled</i> , 2023, , 1-1.	0.1	0
214	A Case of Disseminated Herpes Zoster With Polyneuropathy Following the Third Dose of the Pfizer-BioNTech Vaccine. <i>Cureus</i> , 2023, , .	0.2	1
215	Corneal nerve changes in herpes zoster ophthalmicus: a prospective longitudinal in vivo confocal microscopy study. <i>Eye</i> , 2023, 37, 3033-3040.	1.1	0
216	Disseminated varicella zoster virus infection following live attenuated herpes zoster vaccine: descriptive analysis of reports to Australia's spontaneous vaccine pharmacovigilance system, 2016-2020. <i>BMJ Open</i> , 2023, 13, e067287.	0.8	3
217	Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?. <i>Respiratory Research</i> , 2023, 24, .	1.4	7
218	Epidemiology of Herpes Zoster in the pre-vaccination era: establishing the baseline for vaccination programme's impact in Spain. <i>Eurosurveillance</i> , 2023, 28, .	3.9	4
221	Exploring the causal role of the immune response to varicella-zoster virus on multiple traits: a phenome-wide Mendelian randomization study. <i>BMC Medicine</i> , 2023, 21, .	2.3	1
227	Zoster Vaccines. , 2023, , 1334-1349.e7.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------